论文部分内容阅读
目的探讨pRb蛋白在浆液性卵巢肿瘤中的表达及其临床意义,为卵巢癌的治疗提供依据。方法选择91例卵巢浆液性肿瘤石蜡包埋组织,包括良性肿瘤20例,交界性肿瘤15例,原发性浆液性囊腺瘤56例和相应的有癌转移的盆腔淋巴结24例,以10例正常卵巢组织做对照,应用免疫组织化学染色SP法检测pRb蛋白的表达情况,分析其与浆液性卵巢肿瘤良恶性、浆液性囊腺癌组织学分级,FIGO分期及预后的关系。结果浆液性卵巢组织中pRb蛋白的表达阳性率为46.2%,明显低于正常卵巢组织(90%),而卵巢浆液性良、恶性肿瘤之间,高分化和中低分化浆液性囊腺癌之间,早期和中晚期浆液性囊腺癌之间pRb蛋白表达阳性率无明显差异(p>0.05),pRb蛋白表达阳性和阴性浆液性卵巢癌患者术后生存率也无明显不同(p>0.05)。结论pRb蛋白减少或缺失有利于细胞周期加速转换和肿瘤性疾病的发生,但与浆液性卵巢癌分化程度、FIGO分期及预后的关系有待进一步研究。
Objective To investigate the expression of pRb protein in serous ovarian tumors and its clinical significance, and provide evidence for the treatment of ovarian cancer. Methods 91 cases of ovarian serous paraffin-embedded tissues were selected, including 20 cases of benign tumors, 15 cases of borderline tumors, 56 cases of primary serous cystadenomas and 24 cases of corresponding pelvic lymph nodes with metastasis. Ten cases Normal ovarian tissue as a control, the expression of pRb protein was detected by immunohistochemical SP method, and its relationship with benign and malignant serous ovarian tumors, serous cystadenocarcinoma histological grade, FIGO staging and prognosis. Results The positive expression rate of pRb protein in serous ovarian tissue was 46.2%, which was significantly lower than that in normal ovarian tissue (90%). However, the ovarian serous good and malignant tumor, There was no significant difference in the positive rate of pRb protein expression between early and advanced serous cystadenocarcinoma (p> 0.05), but there was no significant difference in the survival rate between pRb protein positive and negative serous ovarian cancer patients (p> 0.05 ). Conclusion The decrease or deletion of pRb protein is beneficial to the accelerated cell cycle transition and the development of neoplastic diseases. However, the relationship with the degree of differentiation, FIGO stage and prognosis remains to be further studied.